AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22947882 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR intervention
Number of subjects: 62
Study 22947882 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 20194302 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral neurocardiac training (BNT)
Number of subjects: 65
Study 20194302 — intervention group
Group type: COMPARATOR
Intervention: Active control (autogenic relaxation)
Number of subjects: 65
Study 17536128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate, high fat diet (LC)
Number of subjects: 29
Study 17536128 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate, low fat diet (HC)
Number of subjects: 29
Study 17536128 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 17536128 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary 8-epi
Number of subjects: 29
Study 15542567 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 40% of the maximal torque, sustained until endurance.
Number of subjects: 11
Study 12188391 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dexamethasone
Number of subjects: 44
Study 12188391 — intervention group
Group type: COMPARATOR
Intervention: Megadose methylprednisolone
Number of subjects: 44
Study 10192666 — intervention group
Group type: EXPERIMENTAL
Intervention: butylcyanoacrylate
Number of subjects: 94
Study 10192666 — intervention group
Group type: COMPARATOR
Intervention: octylcyanoacrylate
Number of subjects: 94
Study 7752655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg daily (group I)
Number of subjects: 18
Study 7752655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg daily (group II)
Number of subjects: 18
Study 7752655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg daily (group III)
Number of subjects: 18
Study 7752655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine (50 mg and 100 mg)
Number of subjects: 18
Study 1963691 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol alone
Number of subjects: 8
Study 1963691 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol combined with neostigmine
Number of subjects: 8
Study 1963691 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 8
Study 1963691 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 8
Study 7286055 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhydrous crystalline theophylline 250 mg (rectal administration)
Number of subjects: 9
Study 7286055 — intervention group
Group type: COMPARATOR
Intervention: Microcrystalline theophylline 250 mg (oral administration)
Number of subjects: 9
Study 30542798 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0
Study 30542798 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 0
Study 29934056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin (200 mg twice daily, orally)
Number of subjects: 212
Study 29934056 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg four-times daily, orally)
Number of subjects: 212
Study 27582448 — intervention group
Group type: EXPERIMENTAL
Intervention: Community treatment orders (CTOs)
Number of subjects: 0
Study 24861389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 15
Study 24861389 — intervention group
Group type: COMPARATOR
Intervention: Suturing (Control)
Number of subjects: 15
Study 22884569 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately Sequential Bilateral Cataract Surgery (ISBCS)
Number of subjects: 1614
Study 22884569 — intervention group
Group type: COMPARATOR
Intervention: Delayed Sequential Bilateral Cataract Surgery (DSBCS)
Number of subjects: 1614
Study 19396775 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybiane (antioxidants combination)
Number of subjects: 24
Study 19396775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17502536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print (n=86)
Number of subjects: 249
Study 17502536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Internet (n=81)
Number of subjects: 249
Study 17502536 — intervention group
Group type: COMPARATOR
Intervention: Standard Internet (n=82)
Number of subjects: 249
Study 15309206 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenic growth factors (e.g., vascular endothelial growth factors, fibroblast growth factor)
Number of subjects: 0
Study 15309206 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis
Number of subjects: 0
Study 15309206 — intervention group
Group type: COMPARATOR
Intervention: Double-blind randomized placebo controlled studies
Number of subjects: 0
Study 11999819 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaderm
Number of subjects: 126
Study 11999819 — intervention group
Group type: COMPARATOR
Intervention: Tensoplast
Number of subjects: 126
Study 9627295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.37 mg/d) for 1 year
Number of subjects: 54
Study 9627295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.37 mg/d) plus spironolactone (100 mg/d) for 1 year
Number of subjects: 54
Study 9627295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.37 mg/d) plus spironolactone (100 mg/d) for 2 years
Number of subjects: 54
Study 9627295 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (100 mg/d) for 1 year
Number of subjects: 54
Study 7946851 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in management of malignant hyperthermia (group B)
Number of subjects: 28
Study 7946851 — intervention group
Group type: COMPARATOR
Intervention: Training in management of anaphylactic shock (group A)
Number of subjects: 28
Study 3661644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal blood (whole blood dilutions from 1/100 to 1/12,800)
Number of subjects: 2
Study 3661644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal blood (12.5 microliter of blood in the 5-ml test chamber)
Number of subjects: 2
Study 3661644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal blood (1.04 microliter of blood in the test chamber)
Number of subjects: 2
Study 3661644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal blood (12-fold change in concentration)
Number of subjects: 2
Study 31935109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Wingate anaerobic test (WAnTmean)
Number of subjects: 14
Study 31935109 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen consumption
Number of subjects: 14
Study 31935109 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory compensation threshold (VT2)
Number of subjects: 14
Study 31935109 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal lactate steady state (MLSS)
Number of subjects: 14
Study 29281930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy (SIT)
Number of subjects: 31
Study 29281930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 28822516 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 60
Study 28822516 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 60
Study 26420303 — intervention group
Group type: EXPERIMENTAL
Intervention: ForeSite PT™ system with the liquid-crystal display monitor turned on
Number of subjects: 678
Study 26420303 — intervention group
Group type: COMPARATOR
Intervention: ForeSite PT™ system with monitor turned off
Number of subjects: 678
Study 26420303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 678
Study 23717827 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered (controllable) painful skin stimuli
Number of subjects: 50
Study 23717827 — intervention group
Group type: COMPARATOR
Intervention: Experimenter-administered (uncontrollable) painful skin stimuli
Number of subjects: 50
Study 23717827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both controllable and uncontrollable stimuli
Number of subjects: 50
Study 22027728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dior PCB
Number of subjects: 57
Study 22027728 — intervention group
Group type: COMPARATOR
Intervention: Taxus DES
Number of subjects: 57
Study 18470775 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month family intervention
Number of subjects: 92
Study 18470775 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 92
Study 12643887 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BA)
Number of subjects: 3812
Study 12643887 — intervention group
Group type: COMPARATOR
Intervention: Stented Angioplasty
Number of subjects: 3812
Study 10470982 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 10470982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7784719 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD-CPR)
Number of subjects: 6
Study 7784719 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 6
Study 2142013 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PAF (3-422 micrograms)
Number of subjects: 12
Study 2142013 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-medicated PAF challenge
Number of subjects: 12
Study 2142013 — intervention group
Group type: EXPERIMENTAL
Intervention: GR32191B (thromboxane receptor antagonist)
Number of subjects: 12
Study 2142013 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 12
Study 644461 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with dimethyl triazeno imidazole carboxamide (DTIC)
Number of subjects: 70
Study 644461 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with bacillus Calmette‐Guerin (BCG)
Number of subjects: 70
Study 644461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoimmunotherapy
Number of subjects: 70
Study 31896155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal treatment for 2 days
Number of subjects: 15
Study 31896155 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (T2DM-adapted diet)
Number of subjects: 15
Study 31447123 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with dexamethasone (4 mg/mL) and gel lidocaine, applied on the negative electrode at 5 mA for 15 minutes.
Number of subjects: 24
Study 31447123 — intervention group
Group type: COMPARATOR
Intervention: Galvanic current with base gel solution on both electrodes.
Number of subjects: 24
Study 28419032 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐directed home exercise program for 10 weeks
Number of subjects: 120
Study 28419032 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol for physical therapy (in-home visits for 2 weeks followed by outpatient therapy for 8 weeks)
Number of subjects: 120
Study 25719610 — intervention group
Group type: EXPERIMENTAL
Intervention: high VT + ZEEP group (10-12 ml/kg PBW)
Number of subjects: 69
Study 25719610 — intervention group
Group type: EXPERIMENTAL
Intervention: low VT + PEEP group (6-8 ml/kg PBW with 8 cm H2O PEEP)
Number of subjects: 69
Study 25719610 — intervention group
Group type: EXPERIMENTAL
Intervention: low VT + PEEP + RMs group (6-8 ml/kg PBW with 8 cm H2O PEEP and recruitment maneuvers)
Number of subjects: 69
Study 25719610 — intervention group
Group type: COMPARATOR
Intervention: high VT + ZEEP group
Number of subjects: 69
Study 25719610 — intervention group
Group type: EXPERIMENTAL
Intervention: low VT + PEEP + RMs group
Number of subjects: 69
Study 22957802 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel words
Number of subjects: 32
Study 22957802 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic gestures
Number of subjects: 32
Study 22957802 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel words and novel symbolic gestures
Number of subjects: 32
Study 21810227 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (3 cycles of ECC: epirubicin, cisplatin, and capecitabine) followed by surgery and either postoperative chemotherapy (3 cycles of ECC) or concurrent chemoradiotherapy (45 Gy, cisplatin, and capecitabine)
Number of subjects: 0
Study 21810227 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemoradiotherapy (45 Gy, cisplatin, and capecitabine)
Number of subjects: 0
Study 19208697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) with a school-based intervention program based on the Theory of Planned Behaviour (TPB) for 1 year.
Number of subjects: 646
Study 19208697 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no intervention.
Number of subjects: 646
Study 19208697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) with a school-based intervention program based on the TPB for 1 year.
Number of subjects: 646
Study 17510716 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system
Number of subjects: 26
Study 17510716 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 26
Study 15390237 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioSeal
Number of subjects: 122
Study 15390237 — intervention group
Group type: COMPARATOR
Intervention: Femostop
Number of subjects: 122
Study 11429341 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) at 2 L/min
Number of subjects: 16
Study 11429341 — intervention group
Group type: COMPARATOR
Intervention: Fresh gas flow (FGF) at 6 L/min
Number of subjects: 16
Study 11429341 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced anesthesiologists (>8 yr experience)
Number of subjects: 16
Study 11429341 — intervention group
Group type: COMPARATOR
Intervention: Less experienced anesthesiologists (<2 yr experience)
Number of subjects: 16
Study 9508190 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 100 mg/m2 on day 1 and 5‐FU 1,000 mg/m2/d by continuous infusion for 96 hours (days 1 to 4) without interferon alfa-2b (arm A)
Number of subjects: 122
Study 9508190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 on day 1 and 5‐FU 1,000 mg/m2/d by continuous infusion for 96 hours (days 1 to 4) with interferon alfa-2b (arm B)
Number of subjects: 122
Study 8070511 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms of prostaglandin E1 (PGE1) administered by intravenous infusion
Number of subjects: 12
Study 8070511 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered by intravenous infusion
Number of subjects: 12
Study 2903581 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg orally 4 times a day
Number of subjects: 75
Study 2903581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31075151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower barometric pressure (BMP)
Number of subjects: 48
Study 31075151 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress levels
Number of subjects: 48
Study 31075151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-group of patients (n=8)
Number of subjects: 48
Study 31075151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BMP
Number of subjects: 48
Study 27513367 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha and interleukin 2
Number of subjects: 69
Study 27513367 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha, interleukin 2, and bevacizumab
Number of subjects: 69
Study 27513367 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (interferon alpha and interleukin 2)
Number of subjects: 69
Study 27513367 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenesis inhibitors
Number of subjects: 69
Study 27513367 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapies
Number of subjects: 69
Study 25465191 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy/pre-operative chemotherapy
Number of subjects: 635
Study 25465191 — intervention group
Group type: COMPARATOR
Intervention: Immediate nephrectomy
Number of subjects: 635
Study 25465191 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 635
Study 25465191 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, anaplasia, tumour size, lymph nodes metastases and stage
Number of subjects: 635
Study 23356247 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ω-3 fatty acid ethyl esters (3.2 g/day)
Number of subjects: 0
Study 23356247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21114514 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 1877
Study 21114514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride treatment
Number of subjects: 1877
Study 21114514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 1877
Study 21114514 — intervention group
Group type: COMPARATOR
Intervention: Gender (Boys vs Girls)
Number of subjects: 1877
Study 19732444 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Weaning (SmartCare)
Number of subjects: 90
Study 19732444 — intervention group
Group type: COMPARATOR
Intervention: Protocolized Weaning
Number of subjects: 90
Study 17721955 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral intervention
Number of subjects: 22
Study 17721955 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 15087963 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive technique for inserting a standard dynamic hip screw
Number of subjects: 0
Study 15087963 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique for inserting a standard dynamic hip screw
Number of subjects: 0
Study 11179537 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhenium-188 liquid-filled balloon system
Number of subjects: 21
Study 10079038 — intervention group
Group type: EXPERIMENTAL
Intervention: Rey Auditory Verbal Learning Test (RAVLT)
Number of subjects: 220
Study 8071277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 100-500 mg/day
Number of subjects: 180
Study 8071277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 50-250 mg/day
Number of subjects: 180
Study 8071277 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 50-250 mg/day
Number of subjects: 180
Study 8071277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2-10 capsules/day)
Number of subjects: 180
Study 8071277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (both dosage groups)
Number of subjects: 180
Study 8071277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone and Imipramine
Number of subjects: 180
Study 3289961 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine inhalation
Number of subjects: 0
Study 3289961 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcholine inhalation
Number of subjects: 0
Study 3289961 — intervention group
Group type: COMPARATOR
Intervention: Buffered saline (control)
Number of subjects: 0
Study 31808297 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched implants (Group I)
Number of subjects: 70
Study 31808297 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched implants (Group II)
Number of subjects: 70
Study 31808297 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-matched implants (Group III)
Number of subjects: 70
Study 30048322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone and Propranolol (OxProp) for 1 year
Number of subjects: 480
Study 30048322 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 480
Study 27939652 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and mobility training (BMT)
Number of subjects: 42
Study 27939652 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and mobility plus cognitive training (BMT+C)
Number of subjects: 42
Study 27939652 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 26628263 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic injections (2 mL 0.5% lidocaine without a vasoconstrictor)
Number of subjects: 30
Study 26628263 — intervention group
Group type: COMPARATOR
Intervention: Ischemic compression via physical therapy (administered three times for 60 seconds each with 30 seconds rest)
Number of subjects: 30
Study 23348954 — intervention group
Group type: EXPERIMENTAL
Intervention: 20° Trendelenburg position
Number of subjects: 47
Study 23348954 — intervention group
Group type: EXPERIMENTAL
Intervention: 25° Trendelenburg position
Number of subjects: 47
Study 23348954 — intervention group
Group type: EXPERIMENTAL
Intervention: 30° Trendelenburg position
Number of subjects: 47
Study 23348954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum with head-down position in RALP
Number of subjects: 47
Study 21445092 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (s.c., 240/80 mg, n=207)
Number of subjects: 610
Study 21445092 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (s.c., 240/160 mg, n=202)
Number of subjects: 610
Study 21445092 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (i.m., 7.5 mg, n=201)
Number of subjects: 610
Study 19004195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at bilateral Shaoze (SI 1)
Number of subjects: 92
Study 19004195 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture at bilateral Shangyang (LI 1)
Number of subjects: 92
Study 16931613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatorade
Number of subjects: 75
Study 16931613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedialyte
Number of subjects: 75
Study 16931613 — intervention group
Group type: EXPERIMENTAL
Intervention: N-ORS
Number of subjects: 75
Study 15625463 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-based computer-assisted surgery (CAS)
Number of subjects: 24
Study 15625463 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 24
Study 11028723 — intervention group
Group type: EXPERIMENTAL
Intervention: IT tetracaine 15 mg + neostigmine 50 microg
Number of subjects: 60
Study 11028723 — intervention group
Group type: EXPERIMENTAL
Intervention: IT tetracaine 15 mg + neostigmine 100 microg
Number of subjects: 60
Study 11028723 — intervention group
Group type: COMPARATOR
Intervention: IT tetracaine 15 mg
Number of subjects: 60
Study 9483407 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipine
Number of subjects: 0